DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York

Rhea-AI Summary

DBV Technologies, a clinical-stage biopharmaceutical company, will present at the JMP Securities Life Sciences Conference in New York on June 16, 2022, at 12:00 p.m. ET. CEO Daniel Tassé and CMO Dr. Pharis Mohideen will participate in a fireside chat. Investors can access a live webcast of the event on the company's website, with a replay available afterward. DBV Technologies is focused on developing Viaskin™, an innovative platform for non-invasive immunotherapy targeting food allergies, including ongoing trials for Viaskin Peanut.

Montrouge, France, June 16, 2022

DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, and Dr. Pharis Mohideen, Chief Medical Officer, will participate in a fireside chat on Thursday, June 16, 2022, at 12:00 p.m. ET at the JMP Securities Life Sciences Conference in New York.

A webcast of the presentation will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/

A replay of the presentation will also be available on DBV Technologies’ website after the event.

About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com

Attachment

• PDF Version

FAQ

What conference will DBV Technologies present at on June 16, 2022?

DBV Technologies will present at the JMP Securities Life Sciences Conference in New York.

Who will represent DBV Technologies at the JMP Securities Conference?

CEO Daniel Tassé and CMO Dr. Pharis Mohideen will represent DBV Technologies.

What time is the presentation by DBV Technologies at the conference?

The presentation will take place at 12:00 p.m. ET on June 16, 2022.

Where can I watch the DBV Technologies presentation online?

The presentation will be available via a live webcast on the company's website.

What is the focus of DBV Technologies' research?

DBV Technologies is developing Viaskin™, a platform for non-invasive immunotherapy targeting food allergies.

What are some ongoing clinical trials by DBV Technologies?

DBV Technologies is conducting ongoing clinical trials for Viaskin Peanut.

What is the stock symbol for DBV Technologies?

The stock symbol for DBV Technologies is DBVT on NASDAQ.